(EW) Edwards Lifesciences - Ratings and Ratios
Heart Valves, Surgical Solutions, Transcatheter Products, Cardiovascular Devices
EW EPS (Earnings per Share)
EW Revenue
Description: EW Edwards Lifesciences
Edwards Lifesciences Corp (NYSE:EW) is a leading provider of innovative cardiovascular disease treatments, offering a range of products for transcatheter heart valve replacement and repair, as well as surgical structural heart solutions. The companys product portfolio includes the Edwards SAPIEN family of valves, PASCAL PRECISION, and Cardioband, among others.
Key performance indicators (KPIs) for Edwards Lifesciences include revenue growth, driven by increasing adoption of its transcatheter heart valve replacement products, and expanding margins due to operational efficiencies. The companys return on equity (RoE) of 45.06% indicates strong profitability. Additionally, Edwards Lifesciences dividend yield and payout ratio can be evaluated to assess its commitment to returning capital to shareholders.
From a competitive landscape perspective, Edwards Lifesciences operates in the health care equipment industry, where it competes with companies such as Medtronic and Abbott Laboratories. The companys market share and competitive positioning can be assessed by analyzing its product offerings, sales force effectiveness, and distribution network.
To further evaluate Edwards Lifesciences investment potential, metrics such as EV/EBITDA, debt-to-equity ratio, and interest coverage ratio can be examined to gauge its financial health and leverage. Furthermore, the companys research and development (R&D) expenses as a percentage of revenue can be analyzed to assess its commitment to innovation and new product development.
EW Stock Overview
| Market Cap in USD | 47,532m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2000-03-27 |
EW Stock Ratings
| Growth Rating | 6.67% |
| Fundamental | 74.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -7.77% |
| Analyst Rating | 3.69 of 5 |
EW Dividends
Currently no dividends paidEW Growth Ratios
| Growth Correlation 3m | 66% |
| Growth Correlation 12m | 84.8% |
| Growth Correlation 5y | -59.7% |
| CAGR 5y | -5.09% |
| CAGR/Max DD 3y | -0.14 |
| CAGR/Mean DD 3y | -0.28 |
| Sharpe Ratio 12m | -0.42 |
| Alpha | -3.89 |
| Beta | 0.674 |
| Volatility | 27.26% |
| Current Volume | 3711.6k |
| Average Volume 20d | 3488k |
| Stop Loss | 73.7 (-3.1%) |
| Signal | -1.67 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (4.14b TTM) > 0 and > 6% of Revenue (6% = 341.1m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 2.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 90.98% (prev 63.13%; Δ 27.85pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 1.20b <= Net Income 4.14b (YES >=105%, WARN >=100%) |
| Net Debt (-2.57b) to EBITDA (1.78b) ratio: -1.44 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (587.9m) change vs 12m ago -2.71% (target <= -2.0% for YES) |
| Gross Margin 78.90% (prev 78.75%; Δ 0.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 48.20% (prev 51.74%; Δ -3.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 82.39 (EBITDA TTM 1.78b / Interest Expense TTM 19.8m) >= 6 (WARN >= 3) |
Altman Z'' 11.99
| (A) 0.38 = (Total Current Assets 6.58b - Total Current Liabilities 1.40b) / Total Assets 13.49b |
| (B) 1.03 = Retained Earnings (Balance) 13.86b / Total Assets 13.49b |
| warn (B) unusual magnitude: 1.03 — check mapping/units |
| (C) 0.14 = EBIT TTM 1.63b / Avg Total Assets 11.79b |
| (D) 4.94 = Book Value of Equity 14.25b / Total Liabilities 2.88b |
| Total Rating: 11.99 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 74.56
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 2.29% = 1.14 |
| 3. FCF Margin 17.76% = 4.44 |
| 4. Debt/Equity 0.06 = 2.50 |
| 5. Debt/Ebitda 0.35 = 2.41 |
| 6. ROIC - WACC 5.38% = 6.73 |
| 7. RoE 41.22% = 2.50 |
| 8. Rev. Trend 49.13% = 2.46 |
| 9. Rev. CAGR 5.60% = 0.70 |
| 10. EPS Trend 24.47% = 0.61 |
| 11. EPS CAGR 0.72% = 0.07 |
What is the price of EW shares?
Over the past week, the price has changed by -5.19%, over one month by -2.82%, over three months by +1.64% and over the past year by +9.65%.
Is Edwards Lifesciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EW is around 67.71 USD . This means that EW is currently overvalued and has a potential downside of -10.97%.
Is EW a buy, sell or hold?
- Strong Buy: 10
- Buy: 4
- Hold: 17
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the EW price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 87.7 | 15.4% |
| Analysts Target Price | 87.7 | 15.4% |
| ValueRay Target Price | 75.5 | -0.8% |
Last update: 2025-09-05 04:42
EW Fundamental Data Overview
CCE Cash And Equivalents = 4.06b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 33.8745
P/E Forward = 29.4985
P/S = 8.3607
P/B = 4.5219
P/EG = 4.3755
Beta = 1.07
Revenue TTM = 5.69b USD
EBIT TTM = 1.63b USD
EBITDA TTM = 1.78b USD
Long Term Debt = 598.0m USD (from longTermDebt, last quarter)
Short Term Debt = 25.9m USD (from shortTermDebt, last quarter)
Debt = 623.9m USD (Calculated: Short Term 25.9m + Long Term 598.0m)
Net Debt = -2.57b USD (from netDebt column, last quarter)
Enterprise Value = 44.09b USD (47.53b + Debt 623.9m - CCE 4.06b)
Interest Coverage Ratio = 82.39 (Ebit TTM 1.63b / Interest Expense TTM 19.8m)
FCF Yield = 2.29% (FCF TTM 1.01b / Enterprise Value 44.09b)
FCF Margin = 17.76% (FCF TTM 1.01b / Revenue TTM 5.69b)
Net Margin = 72.90% (Net Income TTM 4.14b / Revenue TTM 5.69b)
Gross Margin = 78.90% ((Revenue TTM 5.69b - Cost of Revenue TTM 1.20b) / Revenue TTM)
Tobins Q-Ratio = 3.09 (Enterprise Value 44.09b / Book Value Of Equity 14.25b)
Interest Expense / Debt = 3.17% (Interest Expense 19.8m / Debt 623.9m)
Taxrate = 9.82% (152.1m / 1.55b)
NOPAT = 1.47b (EBIT 1.63b * (1 - 9.82%))
Current Ratio = 4.68 (Total Current Assets 6.58b / Total Current Liabilities 1.40b)
Debt / Equity = 0.06 (Debt 623.9m / last Quarter total Stockholder Equity 10.55b)
Debt / EBITDA = 0.35 (Net Debt -2.57b / EBITDA 1.78b)
Debt / FCF = 0.62 (Debt 623.9m / FCF TTM 1.01b)
Total Stockholder Equity = 10.05b (last 4 quarters mean)
RoA = 30.72% (Net Income 4.14b, Total Assets 13.49b )
RoE = 41.22% (Net Income TTM 4.14b / Total Stockholder Equity 10.05b)
RoCE = 15.31% (Ebit 1.63b / (Equity 10.05b + L.T.Debt 598.0m))
RoIC = 13.81% (NOPAT 1.47b / Invested Capital 10.65b)
WACC = 8.43% (E(47.53b)/V(48.16b) * Re(8.50%)) + (D(623.9m)/V(48.16b) * Rd(3.17%) * (1-Tc(0.10)))
Shares Correlation 3-Years: -93.94 | Cagr: -0.55%
Discount Rate = 8.50% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 71.65% ; FCFE base≈821.2m ; Y1≈623.1m ; Y5≈380.6m
Fair Price DCF = 11.27 (DCF Value 6.62b / Shares Outstanding 587.1m; 5y FCF grow -28.62% → 3.0% )
Revenue Correlation: 49.13 | Revenue CAGR: 5.60%
Rev Growth-of-Growth: 10.94
EPS Correlation: 24.47 | EPS CAGR: 0.72%
EPS Growth-of-Growth: 2.47
Additional Sources for EW Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle